ArticleTherapeutic advances in medical oncology2022

Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.

Daisuke Kawakita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.